Clinical Trials
16 trialsNCT03914300 2026-06-01
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06959641 2026-05-22
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT00001160 2026-05-12
Studies on Tumors of the Thyroid
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01398085 2026-05-07
IoN
University College, London
Phase 2/3 Active not recruiting
NCT07545837 2026-04-27
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
Mayo Clinic
Phase NA Not yet recruiting
NCT07529080 2026-04-14
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04948437 2026-04-13
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT05463107 2026-04-13
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT05575440 2026-02-27
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
Mayo Clinic
Recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT02973997 2025-08-29
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Phase 2 Completed
NCT01723202 2025-08-24
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed